Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ginkgo Bioworks HoldingsDNABW 60 Equity-to-Asset is 0.43 as of Jun. 2026, which is 31% below its 10-year median of 0.62. GuruFocus rates DNABW with a GF Score™ of 60/100. The stock has 5 warning signs investors should review. Among 1,415 Biotechnology companies, Ginkgo Bioworks Holdings ranks worse than 71.87% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Ginkgo Bioworks Holdings Equity-to-Asset Related Terms
Ginkgo Bioworks Holdings Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DNABW vs RZLT, EIKN, ARTV: Equity-to-Asset Comparison
For the Biotechnology subindustry, Ginkgo Bioworks Holdings's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ginkgo Bioworks Holdings Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ginkgo Bioworks Holdings's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Ginkgo Bioworks Holdings's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Ginkgo Bioworks Holdings's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ginkgo Bioworks Holdings (DNABW) has a Equity-to-Asset of 0.43 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Ginkgo Bioworks Holdings and its competitors. This is 31% below median its historical median of 0.62. Over the past decade, Ginkgo Bioworks Holdings' Equity-to-Asset has ranged from 0.43 to 0.77. According to the industry distribution chart, Ginkgo Bioworks Holdings ranks #1017 out of 1415 companies in the Biotechnology industry, placing it in the top 71.9%.
Is Ginkgo Bioworks Holdings' Equity-to-Asset too high?
Ginkgo Bioworks Holdings' current Equity-to-Asset of 0.43 is 31% below median its 10-year median of 0.62. Over the past 10 years, this metric has ranged from a low of 0.43 to a high of 0.77. The Biotechnology industry median Equity-to-Asset is 0.68. Ginkgo Bioworks Holdings' value of 0.43 is 36.8% below this industry median. Based on the distribution chart, Ginkgo Bioworks Holdings ranks #1017 out of 1415 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Ginkgo Bioworks Holdings has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does Ginkgo Bioworks Holdings' Equity-to-Asset compare to RZLT and EIKN?
According to the Biotechnology industry distribution chart, Ginkgo Bioworks Holdings ranks #1017 out of 1415 companies for Equity-to-Asset. This places Ginkgo Bioworks Holdings in the lower half of its industry. The industry median Equity-to-Asset is 0.68. Ginkgo Bioworks Holdings' value of 0.43 is 36.8% below this benchmark. Historically, Ginkgo Bioworks Holdings' own Equity-to-Asset has ranged from 0.43 to 0.77 over the past decade. While the company's 10-year median is 0.62 vs. the industry median of 0.68, Ginkgo Bioworks Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,415 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ginkgo Bioworks Holdings's current Equity-to-Asset of 0.43 is 36.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Ginkgo Bioworks Holdings and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ginkgo Bioworks Holdings's current Equity-to-Asset is 0.43, which is 31% below median its own 10-year median of 0.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ginkgo Bioworks Holdings stock overvalued right now?
Ginkgo Bioworks Holdings (DNABW) has a current Equity-to-Asset of 0.43. The current Equity-to-Asset is 0.43, which is 31% below median its 10-year median of 0.62 and 36.8% below the Biotechnology industry median of 0.68. Ginkgo Bioworks Holdings' overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Ginkgo Bioworks Holdings (DNABW), the current Equity-to-Asset is 0.43 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
60GF Score
Get the complete analysis for DNABW
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DNABW has been successfully added to your 
